LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood

Therapeutic Drug Monitoring

Volumn 21, Issue 1, 1999, Pages 116-122

  Kirchner, Gabriele I ^a   Vidal, Christian ^a   Winkler, Michael ^a   Mueller, Lueke ^a   Jacobsen, Wolfgang ^a   Franzke, Anke ^a   Sewing, Karl Friedrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Analytics; Cyclosporine; ESI MS; Immunosuppressants; Macrolides; Metabolites; SDZ RAD

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MASS SPECTROMETRY; METABOLITE; PRIORITY JOURNAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MASS SPECTROMETRY; SIROLIMUS;

EID: 0033060549     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199902000-00018     Document Type: Article

References (34)

1. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986;30:964-74.
2. Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol 1990;4:554-74.
3. Abu-Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991;52:71-7.
4. McCauly J, van Thiel D, Jain AB, et al. The effects of FK506 on renal function after liver transplantation. Transplant Proc 1990; 22:17-20.
5. Thompson CB, June CH, Sullivan EM, et al. Association between cyclosporine neurotoxicity and hypomagnesemia. Lancet 1984;2: 1116-20.
6. Neuhaus P, McMaster P, Calne R, et al. Neurological complicalions in the European multicentre study of FK506 and cyclosporin in primary liver transplantation. Transpl Int 1994;7:27-31.
7. Schachter M. Cyclosporine A and hypertension. J Hypertens 1988; 6:511-6.
8. Devlin J, Williams R, Neuhaus P, et al. Renal complications and development of hypertension in the European study of FK506 and cyclosporin in primary liver transplantation recipients. Transpl Int 1994;7:22-4.
9. Alessiani M, Cillo U, Fung J, et al. Adverse effects of FK506 overdosage after liver transplantation. Transplant Proc 1993;25: 628-34.
10. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38.
11. Lorber MI. Cyclosporine: Lessons learned, future strategies. Clin Transplant 1991;5:505-16.
12. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61
13. Winkler M, Schumann G, Petersen D, et al. Monoclonal fluorescence polarization immunoassay evaluated for monitoring cyclosporine in whole blood after kidney, heart, and liver transplantation. Clin Chem 1992;38:123-6.
14. Lensmeyer GL, Wiebe DA, Carlson DH, et al. Three commercial polyclonal immunoassays for cyclosporine in whole blood compared. II. Cross-reactivity of the antisera with cyclosporine metabolites. Clin Chem 1990;36:119-23.
15. Yatscoff RW, Copeland KR, Faraci CJ. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 1990;36:1969-73.
16. Christians U, Zimmer KO, Wonigeit K, et al. Measurement of cyclosporin A and four metabolites in whole blood by high-performance liquid chromatography. J Chromatogr 1987;413: 121-9.
17. Christians U, Zimmer KO, Wonigeit K, et al. Liquid-chromatographic measurement of cyclosporin A and its metabolites in blood, bile and urine. Clin Chem 1988;34:34-9.
18. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise consensus conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel. Ther Drug Monit 1995;17: 642-54.
19. Vidai C, Kirchner GI, Sewing K-F. Structural elucidation by electrospray-mass spectrometry: An approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD. J Am Soc Mass Spectr 1998;9:1267-74.
20. Kahan BD, Shaw LM, Holt D, et al. Consensus document: Hawk's Cay meeting of therapeutic drug monitoring of cyclosporine. Clin Chem 1990;36:1510-6.
21. Zhang Q, Simpson J, Aboleneen HI. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. Ther Drug Monit 1997; 19:470-6.
22. Streit F, Christians U, Schiebel HM, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 1996;42:1417-25.
23. Yatscoff R, Shaw L. Therapeutic drug monitoring of cyclosporine, FK506, and rapamycin. Ther Drug Monit 1992;14:267-8.
24. Shaw LM, Bowers LD, Demers L, et al. Critical issues in cyclosporine monitoring: Report of the task force on cyclosporine monitoring. Clin Chem 1987;33:1269-88.
25. Winkler M, Ringe B, Baumann J, et al. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK506 for immunosuppression. Clin Chem 1994;40:2247-53.
26. Yatscoff R, LeGatt D, Keenan R, et al. Blood distribution of rapamycin. Transplantation 1993;56:1202-6.
27. Yatscoff RW, Farad C, Bolingbroke P. Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography. Ther Drug Monit 1992;14:138-41.
28. Christians U, Sattler M, Schiebel HM, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 1992;20:186-91.
29. Napoli KL, Kahan BD. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J Chromatogr B;1994;654:111-120.
30. Gonschior A-K, Christians U, Winkler M, et al. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. Ther Drug Monit 1995;17:504-10.
31. Roth W, Beschke K, Jauch R, et al. Fully automated high-performance liquid chromatography. A new chromatograph for pharmacokinetic drug monitoring by direct injection of body fluids. J Chromatogr 1981;222:13-22.
32. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver:identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43: 630-5.
33. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
34. Kolars JC, Stetson PL, Rush BD, et al. Cyclosporine metabolism by P450IIIA in rat enterocytes: Another determinant of oral bioavailability? Transplantation 1992;53:596-602.